Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
4.11
Dollar change
+0.22
Percentage change
5.66
%
IndexRUT P/E94.05 EPS (ttm)0.04 Insider Own5.26% Shs Outstand57.53M Perf Week5.12%
Market Cap236.49M Forward P/E- EPS next Y-0.48 Insider Trans-3.85% Shs Float54.51M Perf Month-8.05%
Income2.51M PEG2.61 EPS next Q0.05 Inst Own89.56% Short Float5.51% Perf Quarter-4.42%
Sales192.64M P/S1.23 EPS this Y-75.00% Inst Trans-1.89% Short Ratio3.08 Perf Half Y-11.61%
Book/sh9.47 P/B0.43 EPS next Y-4900.00% ROA0.39% Short Interest3.00M Perf Year-39.47%
Cash/sh6.75 P/C0.61 EPS next 5Y36.10% ROE0.47% 52W Range3.30 - 7.00 Perf YTD-2.61%
Dividend Est.- P/FCF19.04 EPS past 5Y-37.98% ROI0.45% 52W High-41.29% Beta0.75
Dividend TTM- Quick Ratio4.92 Sales past 5Y1.11% Gross Margin91.23% 52W Low24.73% ATR (14)0.17
Dividend Ex-Date- Current Ratio4.94 EPS Y/Y TTM-59.74% Oper. Margin-7.24% RSI (14)56.29 Volatility3.69% 4.15%
Employees203 Debt/Eq0.02 Sales Y/Y TTM-24.27% Profit Margin1.30% Recom3.00 Target Price4.25
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-134.75% Payout0.00% Rel Volume1.41 Prev Close3.89
Sales Surprise22.35% EPS Surprise55.56% Sales Q/Q-29.79% EarningsFeb 07 AMC Avg Volume974.27K Price4.11
SMA203.85% SMA503.30% SMA200-12.05% Trades Volume1,370,570 Change5.66%
Date Action Analyst Rating Change Price Target Change
Feb-25-22Downgrade Jefferies Buy → Hold $24 → $12
May-12-21Initiated BofA Securities Buy $22
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Mar-07-24 10:47AM
Mar-06-24 11:55PM
07:00AM
Feb-14-24 04:22AM
Feb-12-24 12:20PM
09:38AM Loading…
Feb-08-24 09:38AM
07:06AM
Feb-07-24 05:02PM
04:26PM
04:02PM
Feb-05-24 08:00AM
Jan-31-24 04:30PM
09:00AM
Jan-30-24 12:35PM
01:02AM
07:00PM Loading…
Jan-29-24 07:00PM
Jan-25-24 10:05PM
01:07PM
Jan-23-24 09:15AM
Jan-19-24 03:56PM
Jan-17-24 03:46PM
Jan-12-24 12:21PM
Jan-04-24 04:30PM
Dec-07-23 07:00AM
Dec-05-23 09:17AM
Dec-04-23 06:00PM
Nov-10-23 11:45AM
Nov-09-23 04:30PM
06:01AM
Nov-08-23 05:50PM
05:25PM Loading…
05:25PM
04:01PM
Nov-01-23 05:00PM
Oct-20-23 07:00AM
Oct-05-23 06:30PM
Sep-20-23 12:28PM
Sep-06-23 05:30PM
Sep-05-23 02:36PM
Sep-01-23 06:51PM
09:35AM
09:18AM
Aug-01-23 09:25AM
Jul-28-23 06:18AM
Jul-27-23 04:07PM
04:01PM
Jul-20-23 04:30PM
Jun-21-23 08:00PM
Jun-05-23 07:00AM
Jun-01-23 09:41PM
09:31PM
May-25-23 03:06PM
07:00AM
May-10-23 02:26PM
May-04-23 06:00PM
05:53AM
May-03-23 04:17PM
04:01PM
May-02-23 06:40PM
12:46PM
Apr-27-23 06:00PM
Apr-26-23 08:00PM
Apr-04-23 06:04AM
Mar-29-23 10:20AM
Mar-28-23 01:26PM
Mar-17-23 07:00AM
Feb-22-23 05:38AM
Feb-09-23 06:48PM
02:29PM
02:24PM
Feb-08-23 04:01PM
Feb-01-23 06:30PM
Jan-12-23 07:55AM
Jan-06-23 09:00AM
Dec-19-22 03:18PM
12:50PM
07:00AM
Dec-16-22 02:54PM
Dec-14-22 03:15PM
Dec-13-22 03:15PM
Dec-05-22 01:40PM
Dec-02-22 07:00AM
Nov-09-22 05:28AM
Nov-08-22 08:30PM
Nov-03-22 03:24PM
Nov-02-22 05:25PM
04:01PM
Oct-27-22 09:40AM
Oct-26-22 06:00PM
Oct-21-22 02:00PM
Oct-20-22 09:40AM
Oct-18-22 06:50AM
Oct-11-22 09:40AM
Oct-04-22 09:40AM
Sep-29-22 04:30PM
Sep-08-22 06:00PM
Sep-07-22 06:38PM
Sep-04-22 09:47AM
Aug-03-22 05:25PM
04:01PM
Jul-27-22 05:30PM
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Polymeropoulos Mihael HristosPresident and CEOMar 05 '24Sale4.1324,288100,2731,871,730Mar 06 04:47 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 05 '24Sale4.219,22938,830129,789Mar 06 04:48 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 05 '24Sale4.208,90237,411231,014Mar 06 04:46 PM
Williams TimothySVP & General CounselMar 05 '24Sale4.188,94137,396196,825Mar 06 04:50 PM
Birznieks GuntherSVP, Business DevelopmentMar 05 '24Sale4.138,68435,884313,569Mar 06 04:46 PM
Polymeropoulos Mihael HristosPresident and CEOMar 04 '24Sale4.2430,884131,0661,896,018Mar 06 04:47 PM
Birznieks GuntherSVP, Business DevelopmentMar 04 '24Sale4.308,72737,495322,253Mar 06 04:46 PM
Williams TimothySVP & General CounselMar 04 '24Sale4.418,14735,917205,766Mar 06 04:50 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 04 '24Sale4.417,49833,091139,018Mar 06 04:48 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 04 '24Sale4.485,79825,982239,916Mar 06 04:46 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 21 '23Sale5.843,72421,748113,816Aug 23 04:23 PM
Mitchell Stephen RayDirectorAug 10 '23Sale6.056,50039,34929,328Aug 11 04:36 PM
Moran Kevin PatrickSVP, CFO & TreasurerJul 28 '23Sale6.302,21213,945120,714Aug 01 04:30 PM
Moran Kevin PatrickSVP, CFO & TreasurerJun 15 '23Sale6.2916,000100,710122,926Jun 20 04:34 PM
Williams TimothySVP & General CounselJun 13 '23Sale6.5614,60095,75488,913Jun 15 04:20 PM